ZAVICEFTA® (CEFTAZIDIME AND AVIBACTAM)| Paediatric Dosing

This site is intended only for healthcare professionals resident in the Republic of Ireland

Log out

Our medicines

Therapy areas

Explore content

Materials

Videos

Podcasts

Let’s connect

Let's connect

About

Broad Coverage

Indications

Efficacy

Limited Treatment Options

Safety

Dosing

Adult Dosing

Paediatric Dosing

ZAVICEFTA (ceftazidime/avibactam) provides dosing options to treat paediatric patients aged 3 months to <18 years with consistent dosing across indications¹

Dosage in paediatric patients aged 3 months to <18 years with CrCl* >50 mL/min/1.73 m² (refer to SmPC for full dosing information)^†‡§

Scroll left to view table

Age Group	Dose of ceftazidime/ avibactam	Frequency	Infusion time	Duration of treatment
6 months to <18 years	50 mg/kg/12.5 mg/kg to a maximum of 2 g/0.5 g	Every 8 hours	2 hours	cIAI: 5–14 days cUTI, including pyelonephritis:^¶ 5–14 days HAP/VAP: 7–14 days LTO: Guided by the severity of the infection, the pathogen(s) and the patient’s clinical and bacteriological progress^\|\|
3 months to <6 months**	40 mg/kg/ 10 mg/kg	Every 8 hours	2 hours

CrCl estimated using the Schwartz bedside formula for paediatric patients aged 3 months and older.

The dose of ZAVICEFTA in patients with estimated CrCl ≤50 mL/min should be adjusted according to recommended doses.

For the treatment of cIAI and infections due to aerobic Gram-negative organisms in patients with LTO, ZAVICEFTA should be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.

Across all indications, ZAVICEFTA should be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.

The total treatment duration shown may include IV ZAVICEFTA followed by appropriate oral therapy.

There is very limited experience with the use of ZAVICEFTA for more than 14 days.

There is limited experience with the use of ZAVICEFTA in paediatric patients aged 3 months to <6 months. Ceftazidime/avibactam is a combination product in a fixed 4:1 ratio and dosage recommendations are based on the ceftazidime component only.

Prescribing information

Zavicefta® (avibactam sodium, ceftazidime pentahydrate)

Zavicefta® (avibactam sodium, ceftazidime pentahydrate) 2g/0.5g powder for concentrate for
solution for infusion)

Abbreviations:

cIAI, complicated intra-abdominal infection; CrCl, creatinine clearance; cUTI, complicated urinary tract infection; HAP, hospital-acquired pneumonia; LTO, limited treatment options; SmPC, Summary of Product Characteristics; VAP, ventilator-associated pneumonia.

References:

ZAVICEFTA. Summary of Product Characteristics, 2022.

Dosing

Legal Category: S1A

Further information available upon request

PP-ZVA-IRL-0242. December 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Account

Log out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

PP-UNP-IRL-0176. January 2023

You are now leaving PfizerPro

You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.